151. Identification of sitagliptin binding proteins by affinity purification mass spectrometry.
- Author
-
Wang XN, Sim BR, Chen H, Zheng YX, Xue JB, Wang L, Kong WS, Zhou K, Guo SJ, Hou JL, Zhang J, Jiang HW, and Tao SC
- Subjects
- Humans, Adaptor Proteins, Signal Transducing, Carrier Proteins, Hypoglycemic Agents pharmacology, Molecular Docking Simulation, Diabetes Mellitus, Type 2 chemically induced, Dipeptidyl-Peptidase IV Inhibitors pharmacology, Sitagliptin Phosphate pharmacology
- Abstract
Type 2 diabetes mellitus (T2DM) is recognized as a serious public health concern with increasing incidence. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin has been used for the treatment of T2DM worldwide. Although sitagliptin has excellent therapeutic outcome, adverse effects are observed. In addition, previous studies have suggested that sitagliptin may have pleiotropic effects other than treating T2DM. These pieces of evidence point to the importance of further investigation of the molecular mechanisms of sitagliptin, starting from the identification of sitagliptin-binding proteins. In this study, by combining affinity purification mass spectrometry (AP-MS) and stable isotope labeling by amino acids in cell culture (SILAC), we discover seven high-confidence targets that can interact with sitagliptin. Surface plasmon resonance (SPR) assay confirms the binding of sitagliptin to three proteins, i . e ., LYPLAL1, TCP1, and CCAR2, with binding affinities (K
D ) ranging from 50.1 μM to 1490 μM. Molecular docking followed by molecular dynamic (MD) simulation reveals hydrogen binding between sitagliptin and the catalytic triad of LYPLAL1, and also between sitagliptin and the P-loop of ATP-binding pocket of TCP1. Molecular mechanics Poisson-Boltzmann Surface Area (MMPBSA) analysis indicates that sitagliptin can stably bind to LYPLAL1 and TCP1 in active sites, which may have an impact on the functions of these proteins. SPR analysis validates the binding affinity of sitagliptin to TCP1 mutant D88A is ~10 times lower than that to the wild-type TCP1. Our findings provide insights into the sitagliptin-targets interplay and demonstrate the potential of sitagliptin in regulating gluconeogenesis and in anti-tumor drug development.- Published
- 2022
- Full Text
- View/download PDF